All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
Which of the following statements is true regarding CAR T-cell therapies?
A
B
C
D
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Michael Wang, MD Anderson Cancer Center, Houston, US, discussing current therapies for MCL and their combinations.
Symposium | Current therapies for MCL and their combinations
Wang provided an overview of current therapies for MCL, highlighted key clinical data, and offered insights into their clinical application. He also discussed novel therapies and combinations, and potential future directions.
Figure 1. Survival outcomes in the phase III SHINE trial*
Figure 2. Response rates in the phase II OASIS II trial*
Figure 3. Response rates and survival outcomes in the phase II ECHO trial*
Figure 4. Response rates and 2-year survival rates with the BOVen regimen*
Figure 5. Response rates and survival outcomes in the phase I/II BRUIN trial*
Figure 6. Response rates and survival outcomes in the phase II ZUMA-2 trial*
Figure 7. Response rates and survival outcomes in the phase I TRANSCEND NHL 001 trial*
Wang concludes by highlighting the need for novel therapies and combinations, particularly in patients who are not able to receive chimeric antigen receptor (CAR) T-cell therapies.
This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with chronic lymphocytic leukemia do you see in a month?